Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukemia cells.

Chemoresistance and radioresistance are considered one of the primary reasons for therapeutic failure in leukemias and solid tumors. Targeted radiotherapy using monoclonal antibodies radiolabeled with alpha-particles is a promising treatment approach for high-risk leukemia. We found that targeted radiotherapy using monoclonal CD45 antibodies radiolabeled with the alpha-emitter (213)Bi ([(213)Bi]anti-CD45) induces apoptosis, activates apoptosis pathways, and breaks beta-irradiation-, gamma-irradiation-, doxorubicin-, and apoptosis-resistance in leukemia cells. In contrast to beta-irradiation-, gamma-irradiation-, and doxorubicin-mediated apoptosis and DNA damage, [(213)Bi]anti-CD45-induced DNA damage was not repaired, and apoptosis was not inhibited by the nonhomologous end-joining DNA repair mechanism. Depending on the activation of caspase-3, caspase-8, and caspase-9, [(213)Bi]anti-CD45 activated apoptosis pathways in leukemia cells through the mitochondrial pathway but independent of CD95 receptor/CD95 ligand interaction. Furthermore, [(213)Bi]anti-CD45 reversed deficient activation of caspase-3, caspase-8, and caspase-9, deficient cleavage of poly(ADP-ribose) polymerase, and deficient activation of mitochondria in chemoresistant and in radioresistant and apoptosis-resistant leukemia cells. These findings show that [(213)Bi]anti-CD45 is a promising therapeutic agent to break chemoresistance and radioresistance by overcoming DNA repair mechanisms in leukemia cells and provide the foundation for discovery of novel anticancer compounds.

[1]  J. Ajani,et al.  Targeting molecular determinants of tumor chemo-radioresistance. , 2005, Seminars in oncology.

[2]  D. Scheinberg,et al.  Radioimmunoconjugates in acute leukemia treatment: the future is radiant , 2005, Bone Marrow Transplantation.

[3]  Mary Helen Barcellos-Hoff,et al.  Radiation and the microenvironment – tumorigenesis and therapy , 2005, Nature Reviews Cancer.

[4]  C. Apostolidis,et al.  Production of Ac-225 from Th-229 for targeted alpha therapy. , 2005, Analytical chemistry.

[5]  P. Jeggo,et al.  The life and death of DNA-PK , 2005, Oncogene.

[6]  D. Scheinberg,et al.  The Promise of Targeted α-Particle Therapy , 2005 .

[7]  M. Zalutsky,et al.  Radioimmunotherapy with alpha-particle emitting radionuclides. , 2004, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[8]  C. Friesen,et al.  A critical role of glutathione in determining apoptosis sensitivity and resistance in leukemia cells , 2004, Cell Death and Differentiation.

[9]  M. Christmann,et al.  Mechanisms of human DNA repair: an update. , 2003, Toxicology.

[10]  B. Kaina.  DNA damage-triggered apoptosis: critical role of DNA repair, double-strand breaks, cell proliferation and signaling. , 2003, Biochemical pharmacology.

[11]  H. Koyama,et al.  Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193 , 2003, Journal of Biological Chemistry.

[12]  S. Reske,et al.  Beta-irradiation used for systemic radioimmunotherapy induces apoptosis and activates apoptosis pathways in leukaemia cells , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  R R Tice,et al.  Recommendations for conducting the in vivo alkaline Comet assay. 4th International Comet Assay Workshop. , 2003, Mutagenesis.

[14]  J. Humm,et al.  Targeted α particle immunotherapy for myeloid leukemia , 2002 .

[15]  D. Bunjes.  188 Re-labeled Anti-CD66 Monoclonal Antibody in Stem Cell Transplantation for Patients with High-risk Acute Myeloid Leukemia , 2002, Leukemia & lymphoma.

[16]  H. Döhner,et al.  Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. , 2001, Blood.

[17]  M. Hengartner.  The biochemistry of apoptosis , 2000, Nature.

[18]  Rachel L. Allen,et al.  Defying death after DNA damage , 2000, Nature.

[19]  J. Haber.  Partners and pathwaysrepairing a double-strand break. , 2000, Trends in genetics : TIG.

[20]  W. Earnshaw,et al.  Induction of apoptosis by cancer chemotherapy. , 2000, Experimental cell research.

[21]  S. Fulda,et al.  Cytotoxic drugs and the CD95 pathway , 1999, Leukemia.

[22]  J C Reed,et al.  Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases , 1999, The EMBO journal.

[23]  I. Bernstein,et al.  Phase I study of 131I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome , 1999 .

[24]  P. Jeggo,et al.  Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient , 1999, Current Biology.

[25]  S. Fulda,et al.  Induction of CD95 ligand and apoptosis by doxorubicin is modulated by the redox state in chemosensitive- and drug-resistant tumor cells , 1999, Cell Death and Differentiation.

[26]  I. Herr,et al.  Chemotherapeutic drugs sensitize pre-B ALL cells for CD95- and cytotoxic T-lymphocyte-mediated apoptosis , 1999, Leukemia.

[27]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[28]  D. Green,et al.  DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. , 1998, Molecular cell.

[29]  O. Samad,et al.  Nuclear levels and structure from the decays of 213 Bi and 209 Tl , 1998 .

[30]  S. Jackson,et al.  The DNA-dependent protein kinase , 1999 .

[31]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[32]  P. Galle,et al.  Reactive Oxygen Intermediates Are Involved in the Induction of CD95 Ligand mRNA Expression by Cytostatic Drugs in Hepatoma Cells* , 1997, The Journal of Biological Chemistry.

[33]  Guido Kroemer,et al.  The proto-oncogene Bcl-2 and its role in regulating apoptosis , 1997, Nature Medicine.

[34]  P. Galle,et al.  Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. , 1997, The Journal of clinical investigation.

[35]  P. Bergman,et al.  Radioresistance, chemoresistance, and apoptosis resistance. The past, present, and future. , 1997, The Veterinary clinics of North America. Small animal practice.

[36]  I. Herr,et al.  Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells , 1996, Nature Medicine.

[37]  A. Modica,et al.  Detection and characterization of apoptotic peripheral blood lymphocytes in human immunodeficiency virus infection and cancer chemotherapy by a novel flow immunocytometric method. , 1994, Blood.

[38]  M. Brechbiel,et al.  Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. , 1992, Bioconjugate chemistry.

[39]  I Nicoletti,et al.  A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. , 1991, Journal of immunological methods.

[40]  L. T. Dillman,et al.  MIRD : radionuclide data and decay schemes , 1989 .

[41]  H. Waldmann,et al.  IMPORTANCE OF ANTIGEN SPECIFICITY FOR COMPLEMENT‐MEDIATED LYSIS BY MONOCLONAL ANTIBODIES , 1988, European journal of immunology.

[42]  G. Hale,et al.  Therapeutic potential of rat monoclonal antibodies: isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. , 1985, Journal of immunology.